Dr. Reddy's Laboratories Limited (RDY) Down 4.6% — Dump the Shares?
Dr. Reddy's Laboratories Limited (RDY) dropped 4.64% in Friday's session, shedding $0.64 to close at $13.25 on the NYSE. The decline extends a difficult stretch for the stock, which now sits 15.4% below its 52-week high of $15.67 reached on June 26, 2026 — a level that looks increasingly distant as the fundamental headwinds weighing on the company continue to reassert themselves.
Volume came in at approximately 971,000 shares, a sharp discount to the 90-day average of roughly 2.54 million. The notably thin turnover suggests this was not a broad-based flush driven by institutional selling, but the absence of buyers willing to step in at current levels speaks for itself.
Why Dr. Reddy's Laboratories Limited Price is Moving Lower
The dominant force pushing RDY lower is the accelerating deterioration tied to the Revlimid revenue cliff. As exclusivity on the Lenalidomide generic has eroded and competitors have entered the market, North America revenue collapsed 51% year over year in Q4 FY26 — the most visible and damaging single number in a quarter full of bad ones. That sales drop cascaded into an 86% year-over-year plunge in consolidated net profit to ₹220 crore, compounded by a one-time ₹450 crore shelf stock adjustment that hit earnings hard. The sequential comparison offered no comfort either, with profit down roughly 82% from the prior quarter.
The damage extends beyond just the Lenalidomide exposure. Global generics revenue fell 13% year over year, and the pharma services and active ingredients segment declined 5% over the same period — both pointing to pressure that is broader and more structural than a single product roll-off. Gross margin and EBITDA compression followed, and analysts have framed the weak Q4 as reflecting persistent headwinds: 6%–8% annual price erosion across US generics, India margin pressure, and ongoing FDA and US tariff risk. With no positive guidance from management to offset those concerns following the May 12 earnings release, investors have found little reason to hold the line.
Thursday's move on the NSE — a 5.7%–5.9% decline from roughly ₹1,349 to approximately ₹1,270 — reinforced that selling pressure is not confined to a single market or trading session. The pattern reflects a broader repricing as investors rotate away from Indian pharma names carrying patent expiry risk and US generic exposure, and RDY's fundamentals, including a revenue decline of 19.13% on a reported basis, make it difficult to argue the discount is unwarranted.
What is the Dr. Reddy's Laboratories Limited Rating - Should I Sell?
Weiss Ratings assigns RDY a C rating. Current recommendation is Hold.
The rating reflects a company caught between genuine operational strengths and deteriorating top-line performance. On the positive side, ROE of 12.16% and a 12.94% profit margin earn the Excellent Efficiency Index — creditable figures for a generic drug manufacturer navigating one of the most challenging pricing environments in recent memory, where US generics pricing erodes structurally and shelf stock adjustments can swallow an entire quarter's earnings in one line item. The Excellent Solvency Index adds a measure of reassurance, indicating that balance sheet stress is not an immediate concern even as cash generation comes under pressure from the Revlimid fallout.
The weak signals, however, are harder to dismiss. Revenue growth of -19.13% anchors the Weak Growth Index — a stark number that captures the full weight of the North America sales collapse and the broad generics softness. The Weak Total Return Index reflects what investors have experienced holding the stock, and the Weak Volatility Index signals that the ride has been bumpy and is unlikely to smooth out quickly given the structural headwinds still working through the business. A forward P/E of 23.65 is not expensive by pharma standards, but it also isn't cheap for a company posting negative revenue growth with limited near-term visibility on a recovery catalyst.
Within the Health Care sector, RDY sits alongside AbbVie Inc. (ABBV, C), Merck & Co., Inc. (MRK, C), and Pfizer Inc. (PFE, C) — all large-cap names navigating their own patent and pipeline pressures. It ranks below Vertex Pharmaceuticals Incorporated (VRTX, C+) and above Thermo Fisher Scientific Inc. (TMO, C-). That positioning reflects a company that is neither a clear avoid nor a confident buy — squarely in the middle of the quality spectrum, where patience is required and conviction is hard to justify without evidence that the revenue trajectory is stabilizing.
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited (RDY) is a Health Care company with a business built around the development, manufacture, and commercialization of generic pharmaceuticals, branded formulations, biosimilars, and active pharmaceutical ingredients. Founded in India and listed on both the NYSE and Indian exchanges, the company serves patients and healthcare systems across North America, Europe, India, and emerging markets, with a particular historical strength in complex generics targeting high-value, often patent-protected molecules where it could build a first-mover advantage at exclusivity expiry.
The North America generics business has long served as the company's primary earnings engine, with products spanning oncology, dermatology, gastroenterology, and pain management. The Lenalidomide generic — marketed under the Revlimid brand by Celgene and later Bristol-Myers Squibb — exemplified this model at its best, delivering outsized returns during the limited-exclusivity window. That same concentration, however, has amplified the current earnings impact as the exclusivity window closes and multiple competitors arrive, compressing both volume and pricing simultaneously. Beyond generics, the company operates a branded formulations business in India and other emerging markets, offering a degree of revenue diversification that provides some offset but has not been large enough to cushion the North America shortfall.
Dr. Reddy's also maintains an active pharmaceutical ingredients segment supplying both internal manufacturing needs and third-party customers, as well as a pharmaceutical services business serving the contract development and manufacturing market. A meaningful intellectual property portfolio and vertically integrated manufacturing capabilities across multiple FDA-inspected facilities represent competitive advantages that distinguish it from smaller generic peers — though those advantages have not insulated it from the pricing pressure and volume erosion that define the current US generics landscape.
Investor Outlook
Dr. Reddy's Laboratories Limited (RDY) carries a Weiss Rating of C (Hold), reflecting a business with durable operational capabilities that is nonetheless working through a significant earnings reset. Investors should watch for any stabilization signal in North America revenue, management commentary on the pipeline of upcoming product launches capable of filling the revenue gap, and whether the company's India and emerging markets businesses can meaningfully offset the structural pressure in its largest profit pool. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--